Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Zuberbier, Torsten
- dc.contributor.author Ensina, Luis Felipe
- dc.contributor.author Giménez Arnau, Anna Maria
- dc.contributor.author Grattan, Clive
- dc.contributor.author Kocatürk, Emek
- dc.contributor.author Kulthanan, Kanokvalai
- dc.contributor.author Kolkhir, Pavel
- dc.date.accessioned 2025-07-02T06:27:44Z
- dc.date.available 2025-07-02T06:27:44Z
- dc.date.issued 2024
- dc.description.abstract Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without definite triggers) and inducible (with definite and subtype-specific triggers; eg, cold or pressure). Current management guidelines recommend step-up administration of second-generation H1-antihistamines to four-fold the approved dose, followed by omalizumab and ciclosporin. However, in many patients, chronic urticaria does not respond to this linear approach due to heterogeneous underlying mechanisms. A personalised endotype-based approach is emerging based on the identification of autoantibodies and other drivers of urticaria pathogenesis. Over the past decade, clinical trials have presented promising options for targeted treatment of chronic urticaria with the potential for disease modification, including Bruton's tyrosine kinase inhibitors, anti-cytokine therapies, and mast cell depletion. This Therapeutics article focuses on the evidence for these novel drugs and their role in addressing an unmet need for personalised management of patients with chronic urticaria.
- dc.format.mimetype application/pdf
- dc.identifier.citation Zuberbier T, Ensina LF, Giménez-Arnau A, Grattan C, Kocatürk E, Kulthanan K, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024 Jul 27;404(10450):393-404. DOI: 10.1016/S0140-6736(24)00852-3
- dc.identifier.doi http://dx.doi.org/10.1016/S0140-6736(24)00852-3
- dc.identifier.issn 0140-6736
- dc.identifier.uri http://hdl.handle.net/10230/70816
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Lancet. 2024 Jul 27;404(10450):393-404
- dc.rights Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.other Urticària
- dc.title Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion